{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:33:17Z","timestamp":1781350397556,"version":"3.54.1"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>\n            <jats:bold>ABSTRACT<\/jats:bold>\n          <\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Non-tuberculosis mycobacteria (NTM) are extensively drug-resistant organisms that require long-term therapy. The study purpose was to quantify the incidence of and risk factors for antimycobacterial-associated adverse drug events (ADEs) in persons with NTM infections receiving outpatient therapy. A multicenter, retrospective cohort was performed of persons with NTM infections who received antimycobacterial treatment from 2013 to 2024. Inclusion criteria were age \u226518 years, \u22651 month of outpatient treatment, and \u22651 follow-up outpatient visit within 3 months of index encounter.\n              <jats:italic>Mycobacterium avium<\/jats:italic>\n              complex and\n              <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n              complex were excluded. The primary outcome was development of pre-specified treatment-related ADE or acute kidney injury (AKI), thrombocytopenia, and\/or\n              <jats:italic>Clostridioides difficile<\/jats:italic>\n              infection (CDI) through 12 months of therapy. Secondary outcomes included therapy discontinuation due to any treatment-related ADEs. Two hundred patients were included: 14% developed a pre-specified ADE.\n              <jats:italic>Mycobacterium abscessus<\/jats:italic>\n              (29%) was the most common pathogen; most initial regimens included a macrolide (54%), systemic aminoglycoside (24%), \u03b2-lactam (24%), or tetracycline derivative (22%). The most common pre-specified ADEs were thrombocytopenia (9%), AKI (8%), and CDI (&lt;1%). The median (IQR) time-to-ADE was 25 (18\u201338) days from initial outpatient regimen; patients who received aminoglycoside- or oxazolidinone-based therapies were more likely to develop a pre-specified ADE (adjOR, 3.9; 95% CI, 1.7\u20139.2). Therapy discontinuation due to any ADE occurred in 35% of patients; the median (IQR) time-to-any ADE was 32 (21\u201358) days. ADEs in persons with NTM infections are common and occur near the first month of outpatient treatment. Intensified monitoring and\/or use of more tolerable antimycobacterial regimens early in treatment may be an appropriate approach to avoid harms.\n            <\/jats:p>\n            <jats:p>\n              Treatment of non-tuberculosis mycobacteria is complicated by adverse drug events (ADEs). This work quantified the incidence and time course of pre-determined, clinically relevant ADEs (acute kidney injury, thrombocytopenia, and\n              <jats:italic>C. difficile<\/jats:italic>\n              infection), which occurred in 14% of patients within 30 days of outpatient treatment.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01596-24","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:00:30Z","timestamp":1741096830000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis\n            <i>Mycobacterium<\/i>\n            infections in the United States"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":true,"given":"Michael P.","family":"Veve","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital","place":["Detroit, USA"]},{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Kenney","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisar M.","family":"Aljundi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital","place":["Detroit, USA"]},{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Dierker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital","place":["Detroit, USA"]},{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Athans","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital of the University of Pennsylvania","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita B.","family":"Shallal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Henry Ford Hospital","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego","place":["La Jolla, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201503-173OC"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091879"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007083"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/919474"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100517"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0302-1"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.12.011"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S48906"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1085"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr522"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1361"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae128"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02183-3"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab389"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121720"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01596-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01596-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:33:28Z","timestamp":1743744808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01596-24"}},"subtitle":[],"editor":[{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,2]]}},"alternative-id":["10.1128\/aac.01596-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01596-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"2024-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01596-24"}}